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Background: Glycopyrronium bromide (NVA237) is an inhaled long-acting muscarinic antagonist in development
for treatment of COPD. This study compared the efficacy and safety of once-daily (OD) and twice-daily (BID)
glycopyrronium bromide regimens, using a novel model-based approach, in patients with moderate-to-severe
COPD.
Methods: Double-blind, randomized, dose-finding trial with an eight-treatment, two-period, balanced incomplete
block design. Patients (smoking history ≥10 pack-years, post-bronchodilator FEV1 ≥30% and <80% predicted, FEV1/
FVC <0.7) were randomized to one of 16 independent sequences for 28 days. Primary endpoint: mean trough FEV1
at Day 28.
Results: 385 patients (mean age 61.2 years; mean post-bronchodilator FEV1 53% predicted) were randomized;
88.6% completed. All OD and BID dosing regimens produced dose-dependent bronchodilation; at Day 28, increases
in mean trough FEV1 versus placebo were statistically significant for all regimens, ranging from 51 mL
(glycopyrronium bromide 12.5 μg OD) to 160 mL (glycopyrronium bromide 50 μg BID). Pharmacodynamic
steady-state was reached by Day 7. There was a small separation (≤37 mL) between BID and OD dose–response
curves for mean trough FEV1 at steady-state in favour of BID dosing. Over 24 hours, separation between OD and
BID regimens was even smaller (FEV1 AUC0-24h maximum difference for equivalent daily dose regimens: 8 mL).
Dose–response results for FEV1 at 12 hours, FEV1 AUC0-12h and FEV1 AUC0-4h at steady-state showed OD regimens
provided greater improvement over placebo than BID regimens for total daily doses of 25 μg, 50 μg and 100 μg,
while the reverse was true for OD versus BID regimens from 12–24 hours. The 12.5 μg BID dose produced a
marginally higher improvement in trough FEV1 versus placebo than 50 μg OD, however, the response at 12 hours
over placebo was suboptimal (74 mL). Glycopyrronium bromide was safe and well tolerated at all doses.
Conclusions: Glycopyrronium bromide 50 μg OD provides significant bronchodilation over a 24 hour period, and
in terms of FEV1 AUC0-24h is not significantly different than the same total daily dose administered BID. Importantly,
OD dosing may confer better patient adherence. The results are consistent with previous glycopyrronium bromide
studies and support once-daily dosing of glycopyrronium bromide 50 μg in patients with moderate-to-severe
COPD.
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Chronic obstructive pulmonary disease (COPD) is char-
acterized by progressive airflow obstruction, resulting in
airflow limitation that is only partially reversible [1,2].
COPD is a major cause of morbidity and mortality
worldwide, and represents a substantial economic and
social burden that is expected to increase [1].
Bronchodilators are the cornerstone treatment for all
COPD severity stages. Long-acting muscarinic antago-
nists (LAMAs) are one of the main classes of bronchodi-
lators used for the treatment of COPD. The optimal
characteristics of a LAMA for use in COPD would be to
provide the following: clinically meaningful bronchodila-
tion, in addition to symptom relief, prevention of disease
progression, improvement in exercise tolerance and
health status, prevention and treatment of complications
and exacerbations and a reduction in mortality risk
[1,3,4]. Other characteristics of an ideal LAMA would
include strong selectivity for muscarinic type 3 (M3)
receptors, long duration of action, rapid onset of action,
and a good safety and tolerability profile [1,4].
NVA237 is a dry-powder formulation of glycopyrronium
bromide. As with other LAMAs, its bronchodilatory
effects result from blockade of muscarinic type 1 (M1)
and M3 receptors, which are involved in either transmis-
sion of nerve impulses or promotion of contraction in air-
way smooth muscle. Glycopyrronium bromide has a low
oral bioavailability, is selective for M3 over muscarinic
type 2 (M2) receptors, and equilibrates rapidly with M3
receptors [4]. Dosages of 50 μg and 100 μg once daily
(OD) have been identified in a phase II trial as providing
effective bronchodilation, with clinically meaningful
improvements in forced expiratory volume in 1 second
(FEV1) over 7 days’ treatment. Compared with open-label
tiotropium 18 μg OD, glycopyrronium bromide 50 μg OD
appears similar in terms of bronchodilatory efficacy and
duration of action, although the latter has a more rapid
onset of action [5,6]. Post-hoc analysis has also confirmed
superior bronchodilation and responder rates with glyco-
pyrronium bromide 50 μg, compared with lower doses
(12.5 and 25 μg), while tolerability profiles were similar
across the dose range [7]. The efficacy of glycopyrronium
bromide 50 μg OD has been confirmed in a further study,
showing it to provide sustained 24-hour bronchodilation
during 14 days’ treatment [8]. In these studies, glycopyrro-
nium bromide was well tolerated, even at dosages as high
as 200 μg OD (4 times the dosage identified as the lowest
dose producing clinically significant improvements in
bronchodilation) [9]. Based on the results of these earlier
efficacy and safety studies, a dose of 50 μg OD was
selected for further clinical evaluation in Phase III trials.
The present study in patients with stable COPD aimed
to evaluate the efficacy and safety of twice-daily (BID)
dosing regimens for glycopyrronium bromide, versus thesame total daily dose administered on an OD basis, by
fully characterizing the dose–response relationship of
both regimens. The doses evaluated ranged from 12.5 μg
OD to 50 μg BID. Standard statistical methods routinely
applied in bronchodilator studies, such as analysis of co-
variance, are intended to allow direct pairwise compari-
sons. However, these methods are not suitable for
detailed dose–response characterization because they
only provide information on each comparison independ-
ently and not on the dose–response relationship as a
whole. Given the number of pairwise comparisons ne-
cessary to piecewise reconstruct a dose–response rela-
tionship with reasonable resolution, none of the pairwise
comparisons will have adequate precision to allow differ-
entiation across the doses due to sample size limitations.
This fundamental limitation in dose–response assess-
ment for spirometric measures has been discussed previ-
ously [10,11]. For these reasons, a rigorous pre-specified
model-based approach was used to allow definitive esti-
mation of the dose–response and dose–regimen rela-
tionships. This relationship, in turn, was used as the
basis for dose differentiation.
Methods
This study was conducted between April and December
2010 at 50 centres in 9 countries (Belgium, Germany,
Hungary, India, The Netherlands, Poland, Romania, Spain
and USA). The study was performed according to the eth-
ical principles of the Declaration of Helsinki; the protocol
was reviewed by the Independent Ethics Committee or In-
stitutional Review Board for each participating centre. All
patients provided written informed consent before enrol-
ling in the study (Additional file 1: Appendix 1).
Patients
Included in this study were male and female adults aged
≥40 years with stable moderate-to-severe COPD [12]
and a smoking history of ≥10 pack-years (defined as: 20
cigarettes/day for 10 years, or 10 cigarettes/day for
20 years, etc.). Patients were required to have a post-
bronchodilator (45 min after inhalation of 84 μg ipratro-
pium bromide) FEV1 ≥30% and <80% of the predicted
normal, and post-bronchodilator FEV1 to forced vital
capacity (FVC) ratio <0.7 at screening. Patients must
also have been symptomatic, according to daily elec-
tronic diary data collected during a 1-week run-in
period, with a total score ≥1 on at least 4 of the 7 days
prior to Day 1 of the study.
Study exclusion criteria included: hospitalization for
exacerbation of airways disease in the 6 weeks prior to
study start, respiratory tract infection within 4 weeks
prior to study start, prolonged QTc interval at screening
(or history of long QT syndrome), requiring daily oxygen
therapy for chronic hypoxemia, history of asthma, Type
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in the previous 5 years (except localized basal cell car-
cinoma of the skin), or any other clinically relevant med-
ical condition or laboratory abnormality that might have
compromised safety or compliance. Also excluded were
those with history of an untoward reaction to any of the
study drugs, women of child-bearing potential not using
an accepted form of contraception, pregnant women,
and nursing mothers.
Use of inhaled salbutamol/albuterol as rescue medication
was permitted throughout the study (except immediately
before and during study visits, unless absolutely necessary).
Patients taking fixed combinations of inhaled corticoster-
oids (ICS) and long-acting β2-agonists (LABA) were trans-
ferred to the nearest equivalent ICS monotherapy at least
48 hours prior to screening. Use of the following medica-
tions was not permitted during this study: long-acting
anticholinergics (minimum washout period prior to screen-
ing: 7 days), short-acting anticholinergics (8 h), LABAs
(48 h), short-acting β2-agonists other than rescue medica-
tion (6 h), fixed combinations of inhaled short-acting antic-
holinergics and short-acting β2-agonists (8 h), xanthines
(7 days), parenteral or oral corticosteroids (1 month), and
intramuscular depot corticosteroids (3 months). Also pro-
hibited were: any drugs with potential to significantly pro-
long the QT interval (e.g. mizolastin; minimum washout
prior to screening: 14 days or 5 half-lives, whichever was
longer), other investigational drugs (30 days or 5 half-lives,
whichever was longer), non-selective beta-blockers (7 days),
leukotriene antagonists (7 days), cromoglycate (7 days),
Nedocromil (7 days), Ketotifen (7 days), systemic anticholi-
nergics (7 days). Patients who had live attenuated vaccina-
tions within 30 days prior to the screening visit or during
the run-in period were excluded from taking part in the
study (inactivated influenza vaccination, pneumococcal vac-
cination or any other inactivated vaccine was acceptable
provided it was administered ≥48 hours prior to the screen-
ing and/or randomization visit).
Study design
This was a double-blind, randomized, dose-finding trial
utilizing an eight-treatment, two-period, balanced incom-
plete block design. Patients were randomized to one of 16
independent sequences and received two treatments from:
glycopyrronium bromide 12.5 μg OD, 12.5 μg BID, 25 μg
OD, 25 μg BID, 50 μg OD, 50 μg BID, 100 μg OD, or pla-
cebo in a 1:1:1:1:1:1:1:1 ratio, with balanced representation
of each treatment. Patients received study drug for 28 days
in the first treatment period, then entered a 7-day washout
period, during which they continued only with their back-
ground COPD medication, before commencing the sec-
ond 28-day treatment period. All short-acting COPD
medications were thoroughly washed out prior to com-
mencing the second treatment period. Patients receivedtheir first dose of study medication in the clinic between
08:00 and 10:00 in the morning. Patients were instructed
to take study medication every day at home between 08:00
and 10:00 in the morning, and the evening dose 12 hours
later (±15 min), between 20:00 (8 pm) and 22:00 (10 pm).
For patients on OD regimens, active treatment was admi-
nistered in the morning and placebo in the evening, to
maintain blinding of OD versus BID regimens. Patients
were required to attend the study centres for 18 visits.
Study assessments and variables
Efficacy assessments were based on centralized spirometry
(using standardized spirometry equipment with review of data
by qualified personnel at a Contract Research Organization)
FEV1 and FVC were measured on Days 1, 7 and 14 at the
following timepoints relative to the morning dose: 45 and
15 minutes pre-dose and 5 minutes and 1, 2, 4, 8, 10 hours,
11 hours 55 minutes, and 14 hours post dose, with assess-
ments continuing the following day at 20 and 22 hours,
23 hours 15 minutes and 23 hours 45 minutes post dose.
Day 28 spirometry tests followed the same schedule, with
additional assessments at 15 minutes and 3 and 6 hours
post dose.
The primary efficacy variable was trough FEV1 at Day
28 (defined as the mean of the 23 h 15 min and 23 h
45 min post-dose values). Secondary efficacy variables
included FEV1 area under the curve for time 0–24 hours
post dose (AUC0-24h FEV1), FEV1 AUC0-4h, FEV1 AUC0-12h,
FEV1 AUC12-24h, FEV1 at 12 hours and peak FEV1, all mea-
sured after 28 days of treatment. The AUC measures were
standardized by the length of time interval.
Safety assessments consisted of collecting adverse events
(AEs; including their severity and possible relationship to
study drug) and pregnancies, assessing vital signs, and
electrocardiogram (ECG) throughout the study. Haema-
tology, blood chemistry and urinalysis parameters were
assessed at screening and at the final dosing visit in each
treatment period. An independent adjudication committee
was used to classify deaths during the study.
Statistical analyses
A non-linear dose–response modelling approach was used
to evaluate the bronchodilator efficacy of doses administered
either OD or BID after 28 days of treatment (Additional file
2: Appendix 2). Based on previous glycopyrronium bromide
spirometric results [5], the shape of the dose–response curve






where dose represents total daily dose, E0 is the placebo ef-
fect, Emax = the maximum (placebo-adjusted) drug effect,
ED50 = a measure of drug potency interpreted as the dose
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parameter. Further assumptions were that regimen acts as a
potency (ED50) modifier and that a common maximal effect
(Emax) is reached for both regimens. A sensitivity analysis of
trough FEV1, performed relaxing the latter assumption, pro-
vided similar results.
For each spirometry outcome, the actual analysis used
data collected over the entire course of treatment (Days
1, 7, 14 and 28). To reduce potential bias, eight candi-
date models were selected to characterize the bronchodi-
latory dose response over time and were prospectively
specified. Half of the models had a fixed value γ=1 in
the above equation; the other half allowed estimating the
γ parameter. For each set of four models, the longitu-
dinal component either assumed a smooth increase in
FEV1 response from Day 1 to Day 28, or a flat response
at Day 7 onwards. Each model included random terms
to represent inter-individual (patient), inter-occasion
(patient–period) and residual variability, all assumed to
be normally distributed. Each model was further
adjusted using the SAS procedure NLMIXED with the
first-order method (method = FIRO) for: period baseline
FEV1 measurement; FEV1 prior to inhalation and FEV1
45 minutes post inhalation of ipratropium bromide
(components of reversibility at Day 14); smoking status
(current/ex-smoker); baseline ICS use (yes/no); and
period (fixed effect).
Each of the candidate models that were successfully fit-
ted provided an estimate of dose response at Day 28. The
final characterization of dose response relied on model
averaging, i.e. a weighted average of the different models.
Weights for each model were a function of the Bayesian
information criterion (BIC), i.e. models that best repre-
sented the data carried a greater weight in the estimate.
Confidence limits around model-average estimates were
obtained using a simulation-based procedure.
Results were expressed as percentages of the maximal
placebo-adjusted effect of glycopyrronium bromide (Emax)
and treatment differences were summarized for OD and
BID regimens that provided the same total daily dose. No
formal hypothesis testing was performed for this study;
however, 90% confidence intervals (CIs) are presented for
selected analyses.
In order to characterize bronchodilation over the course
of the whole day at steady-state, dose–response modelling
was applied to the measured FEV1 for each spirometry
timepoint separately (using the model assuming a flat dose
response at Day 7 onwards and γ=1) and the results plot-
ted to show the 24-hour profile.
The modified intent-to-treat (ITT) population included
all those patients randomized who received at least one
dose of study medication. These were used in the analysis
of all efficacy variables. The safety population, used in the
analysis of all safety variables, included all those patientswho received at least one dose of study medication, in-
cluding those who may have received it in error (this was
identical to modified ITT population except for allowing
for erroneous drug administration). Safety variables were
analyzed descriptively, with clinically relevant or notable
changes assessed. QTc interval was calculated using
Fridericia’s formula: QTc = QT / 3√RR.
Assuming an overall dropout rate of 17%, a planned
sample size of 360 patients was considered sufficient to
show that the upper limit of the 90% CI (one-sided) for
the maximum BID–OD difference in trough response
falls below 40 mL with 80% chance, when the relative




A total of 385 patients were randomized and received
study medication, with 341 (88.6% of the modified ITT
population) completing the study, providing evaluable
data for 87–96 patients per treatment group. Baseline
demographic and clinical characteristics are shown in
Table 1. The mean age of patients in the study was
61.2 years (range 40–81 years, with the majority of
patients being <65 years of age), 65.0% were male; and
the mean duration of COPD was 7.7 years. Mean post-
bronchodilator FEV1 was 53% predicted.
Efficacy
Primary endpoint: mean trough FEV1 at Day 28
Glycopyrronium bromide reached pharmacodynamic
steady-state by Day 7. At Day 28, all once daily and
twice daily dosing regimens produced dose-dependent
bronchodilation (Figure 1). Furthermore, all glycopyrro-
nium bromide treatment groups had statistically signifi-
cant absolute increases in mean trough FEV1 compared
with placebo. Increases in FEV1 over that seen with pla-
cebo ranged from 51 mL (with glycopyrronium bromide
12.5 μg OD) to 160 mL (with glycopyrronium bromide
50 μg BID), equating to 27-85% of the model-predicted
maximum effect of any glycopyrronium bromide dose
(Table 2). For the primary efficacy variable of mean
trough FEV1, separation between dose–response curves
for OD and BID dosing regimens was observed although
the difference was small, with an estimated difference of
approximately 35 mL, favouring BID, for total daily
doses in the range of 25–50 μg (Figure 1).
Secondary endpoint: FEV1 AUC at Day 28
When FEV1 over the whole 24-hour period post-
morning dose was considered, the separation was sub-
stantially reduced, with OD and BID regimens showing
similar dose–response profiles for FEV1 AUC0-24h for
equivalent total daily doses (Figure 2). The estimated
Table 1 Baseline demographics and clinical characteristics (safety population)
Glycopyrronium
bromide 12.5 μg
OD (n = 89)
Glycopyrronium
bromide 25 μg
OD (n = 96)
Glycopyrronium
bromide 12.5 μg
BID (n = 96)
Glycopyrronium
bromide 50 μg
OD (n = 92)
Glycopyrronium
bromide 25 μg BID
(n = 96)
Glycopyrronium




BID (n = 87)
Placebo
(n = 91)
Age (years), mean (SD) 60.2 (7.77) 60.0 (7.98) 60.9 (7.89) 59.2 (8.14) 61.2 (7.80) 62.1 (7.83) 62.2 (7.74) 63.2 (7.67)
Range 47-79 43-81 40-80 43-80 40-80 40-79 49-81 48-78
Sex, n (%)
Male 56 (62.9) 64 (66.7) 67 (69.8) 56 (60.9) 66 (68.8) 59 (61.5) 59 (67.8) 56 (61.5)
Smoking history, n (%)
Ex-smoker 45 (50.6) 51 (52.1) 50 (52.1) 45 (48.9) 50 (52.1) 57 (59.4) 48 (55.2) 52 (57.1)
Current smoker 44 (49.4) 45 (46.9) 46 (47.9) 47 (51.1) 46 (47.9) 39 (40.6) 39 (44.8) 39 (42.9)
Pack-years, mean (SD) 43.2 (23.05) 39.6 (19.97) 40.9 (19.88) 39.3 (19.91) 42.8 (23.26) 39.8 (19.79) 42.1 (21.17) 40.4 (20.84)
FEV1 pre-bronchodilator (% predicted), n (%)
47 (12) 46 (11) 46 (14) 46 (11) 45 (12) 46 (14) 48 (13) 48 (13)
FEV1 post-bronchodilator (% predicted), n (%)
30- < 50% 34 (38.2) 36 (37.5) 44 (45.8) 34 (37.0) 43 (44.8) 44 (45.8) 34 (39.1) 37 (40.7)
50- < 80% 55 (61.8) 60 (62.5) 52 (54.2) 58 (63.0) 53 (55.2) 52 (54.2) 53 (60.9) 54 (59.3)
FEV1 reversibility,%
Mean (SD) 17 (12) 19 (16) 16 (14) 17 (12) 16 (12) 17 (18) 16 (16) 16 (16)
Median (range) 16 (−11-44) 19 (−16-90) 16 (−43-55) 18 (−18-40) 15 (−13-44) 16 (−43-72) 14 (−21-90) 13(−21-72)
FEV1/FVC (%) post-bronchodilator (%), mean (SD)
46.87 (10.36) 46.76 (8.66) 45.86 (11.12) 46.41 (9.29) 46.15 (10.21) 47.21 (11.72) 47.89 (9.57) 48.22 (10.65)









































Figure 1 Trough FEV1 dose−response results at 24 hours at steady-state (modified intent-to-treat population). Model average placebo-
adjusted values for OD and BID dosing regimens, with 90% confidence limits (red and blue shaded areas, respectively). FEV1: forced expiratory
volume in one second; OD: once daily; BID: twice daily.
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BID regimens was 8 mL over 24 hours, at steady-state.
Differences between the OD and BID regimens for the
total daily doses of 25 μg, 50 μg and 100 μg were small
(Table 2). For the 50 μg OD dose, the treatment differ-
ence over placebo was 123 mL (62% Emax) compared
with 131 mL (66% Emax) for 25 μg BID and 98 mL (49%
Emax) for 12.5 μg BID.
Dose–response results for FEV1 AUC0-4h, FEV1 AUC0-12h,
and FEV1 AUC12-24h at steady-state were also comparable
for OD and dose-equivalent BID regimens (Table 2). For the
50 μg OD dose the treatment difference for FEV1 AUC0-4h
was 165 mL (79.7% Emax) versus 153 mL (73.7% Emax)
for 25 μg BID, and 122 mL (58.9% Emax) for 12.5 μg BID.
The treatment difference for FEV1 AUC0-12h was 152 mL
(73.6% Emax) for 50 μg OD versus 139 mL (67.1% Emax)
for 25 μg BID, and 104 mL (50.5% Emax) for 12.5 μg BID.
Finally, for FEV1 AUC12-24h, the treatment difference was
111 mL (56.4% Emax) for 50 μg OD compared with 141 mL
(71.4% Emax) for 25 μg BID, and 112 mL (56.6% Emax) for
12.5 μg BID (Table 2).
Secondary endpoint: peak FEV1 at Day 28
When peak FEV1 at steady-state was considered, as
anticipated, an advantage was seen for the OD over the
BID regimen (Figure 3). For the 50 μg OD dose the
treatment difference was 168 mL (82% Emax), compared
with 156 mL (76% Emax) for 25 μg BID and 126 mL
(61% Emax) for 12.5 μg BID.
Comparison of spirometric profiles
In general, improvements in spirometric outcomes based
on measurements collected 0–12 hours post-dose (FEV1at 12 h, FEV1 AUC0-4h and FEV1 AUC0-12h) were mar-
ginally greater for the OD regimens than the BID regi-
mens, whereas the opposite was seen over the period
12–24 hours post-dose. The reason for this can best
be visualized through the full spirometry profiles, which
are shown for total daily doses of 25, 50 and 100 μg in
Figure 4. The dose response is apparent in these plots,
as the profiles are shifted upwards with increasing total
daily dose. As can also be seen, the OD profiles were
above the BID profiles over the first 12 hours, and below
over the last 12 hours. Thus, OD dosing shows more
favourable results during the day and BID dosing more
favourable results during the night. Over the whole day,
those differences tend to cancel out which leaves no
meaningful differences between OD and BID dosing in
AUC0-24h (Figure 2).
Figure 4 also shows that the glycopyrronium bromide
50 μg OD regimen is the lowest OD dose that provides
bronchodilation above or around the minimal clinically
important difference (MCID) [12]. Although the 12.5 μg
BID dose produced a marginally higher improvement in
trough FEV1 over placebo than the 50 μg OD dose (Day
28), the response it produced in FEV1 at 12 hours after
28 days of treatment over placebo (i.e. 74 mL) was below
the MCID of 100 mL (the minimum difference that can
be perceived by patients, and which correlates with
fewer relapses following exacerbations) [13].
Safety
The overall incidence of AEs was lower with all glyco-
pyrronium bromide dosages/regimens than with placebo
(Table 3). The most commonly reported AEs were:
COPD (worsening) in the glycopyrronium bromide
Table 2 Dose–response relationship for glycopyrronium bromide treatment regimens: model-averaged analysis of
trough FEV1, FEV1 AUC0-24h, FEV1 AUC0-12h, FEV1 AUC0-4h, and FEV1 AUC12-24h at steady state
Glycopyrronium bromide dose
12.5 μg OD 25 μg OD 12.5 μg BID 50 μg OD 25 μg BID 100 μg OD 50 μg BID
Trough FEV1 at steady state
Absolute increase over
placebo (L), (SE)
0.051 (0.019) 0.079 (0.020) 0.115 (0.021) 0.109 (0.020) 0.141 (0.020) 0.137 (0.019) 0.160 (0.020)
90% CI 0.032, 0.081 0.054, 0.108 0.082, 0.142 0.083, 0.135 0.112, 0.163 0.111, 0.160 0.135, 0.181
% of projected maximum effect of any
glycopyrronium bromide dose* (SE)
27 (11) 42 (12) 62 (14) 59 (12) 76 (13) 73 (12) 85 (11)
90% CI 16, 44 27, 61 37, 82 38, 76 49, 90 49, 87 60, 95
FEV1 AUC0-24h at steady state
Absolute increase over placebo (L), (SE) 0.058 (0.012) 0.089 (0.014) 0.098 (0.015) 0.123 (0.014) 0.131 (0.014) 0.152 (0.012) 0.158 (0.012)
90% CI 0.039, 0.079 0.066, 0.113 0.071, 0.122 0.099, 0.145 0.106, 0.152 0.131, 0.171 0.138, 0.176
% of projected maximum effect of any
glycopyrronium bromide dose* (SE)
29 (7) 45 (8) 49 (9) 62 (8) 66 (8) 76 (6) 79 (6)
90% CI 19, 42 32, 59 34, 64 48, 74 51, 78 65, 85 68, 88
FEV1 AUC0-12h at steady state
Absolute increase over placebo (L), (SE) 0.085 (0.015) 0.121 (0.016) 0.104 (0.016) 0.152 (0.014) 0.139 (0.015) 0.176 (0.012) 0.166 (0.013)
90% CI 0.061, 0.111 0.094, 0.146 0.078, 0.130 0.128, 0.174 0.113, 0.162 0.155, 0.195 0.144, 0.186
% of projected maximum effect of any
glycopyrronium bromide dose* (SE)
41 (8) 58 (8) 51 (8) 74 (6) 67 (7) 85 (4) 80 (5)
90% CI 29, 55 45, 71 37, 64 62, 83 54, 78 76, 91 70, 88
FEV1 AUC0-4h at steady state
Absolute increase over placebo (L), (SE) 0.105 (0.016) 0.138 (0.015) 0.122 (0.016) 0.165 (0.013) 0.153 (0.014) 0.183 (0.012) 0.175 (0.012)
90% CI 0.080, 0.132 0.114, 0.162 0.096, 0.148 0.143, 0.185 0.129, 0.174 0.163, 0.203 0.154, 0.195
% of projected maximum effect of any
glycopyrronium bromide dose* (SE)
51 (8) 67 (7) 59 (8) 80 (6) 74 (7) 88 (5) 84 (6)
90% CI 39, 64 54, 78 46, 72 67, 87 61, 83 78, 93 73, 91
FEV1 AUC12-24h at steady state
Absolute increase over placebo (L), (SE) 0.051 (0.025) 0.079 (0.026) 0.112 (0.027) 0.111 (0.026) 0.141 (0.026) 0.141 (0.027) 0.163 (0.028)
90% CI 0.033, 0.080 0.056, 0.108 0.080, 0.139 0.086, 0.137 0.112, 0.163 0.116, 0.163 0.138, 0.184
% of projected maximum effect of any
glycopyrronium bromide dose* (SE)
26 (11) 40 (12) 57 (14) 56 (13) 71 (14) 71 (13) 82 (13)
90% CI 16, 43 24, 60 31, 78 33, 75 42, 88 43, 86 51, 94
*100 x (effect of this dosage/maximum theoretical effect predicted by model).
OD: once daily; BID: twice daily; SE: standard error; CI: confidence interval; FEV1: forced expiratory volume in one second; AUC: area under the curve.
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http://www.biomedcentral.com/1471-2466/12/7412.5 μg OD and 25 μg BID groups; nasopharyngitis in
the glycopyrronium bromide 25 μg OD, 50 μg OD and
50 μg BID groups; both nasopharyngitis and headache in
the glycopyrronium bromide 100 μg OD and placebo
groups; and dyspnoea and diarrhoea in the glycopyrro-
nium bromide 12.5 μg BID group. However, differences
in AE frequency between treatments were generally
small and there was no difference in severity between
the OD and BID regimens.
The proportion of patients with serious AEs was low
with all treatments and generally occurred during Period
1. Overall, a total of 21 serious AEs were reported by 19
patients, with COPD worsening being most common(reported by 5 patients). Cardiac disorder was reported
in two patients (1 patient in the glycopyrronium brom-
ide 50 μg BID group had ventricular extrasystoles, 1 pa-
tient receiving placebo had angina pectoris). One death
was reported during treatment with glycopyrronium
bromide 50 μg OD during period 2 but was not sus-
pected to be related to study drug.
AEs leading to discontinuation were reported for a
small proportion of patients receiving each treatment; 6
patients (6.7%), 3 patients (3.1%), 1 patient (1.1%), and 3
patients (3.1%) in the glycopyrronium bromide 12.5 μg
OD, 25 μg OD, 50 μg OD, and 100 μg OD treatments,
and for 1 patient (1.0%), 5 patients (5.2%) and 2 patients





















Figure 2 Dose−response results of FEV1 AUC0-24h at steady-state (modified intent-to-treat population). Model average placebo-adjusted
values for OD and BID dosing regimens, with 90% confidence limits (red and blue shaded areas, respectively). FEV1: forced expiratory volume in
one second; AUC: area under the curve; OD: once daily; BID: twice daily.
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http://www.biomedcentral.com/1471-2466/12/74(2.3%) receiving glycopyrronium bromide 12.5 μg BID,
25 μg BID, and 50 μg BID, respectively, and 4 patients
(4.4%) receiving placebo. The most common AE leading
to discontinuation was COPD worsening. One patient
receiving glycopyrronium bromide 50 μg BID had a mild
headache (on Day 2 of Period 1) that lead to discontinu-
ation and was suspected to be related to study drug.
There were no clinically meaningful changes in
haematology or clinical chemistry parameter values dur-
ing the study, and vital signs showed little effect of gly-
copyrronium bromide; in all treatment groups, mean
















Figure 3 Dose−response results of peak FEV1 at steady-state (modifie
dosing regimens, with 90% confidence limits (red and blue shaded areas, r
daily; BID: twice daily.rage for pulse rate (40−90 bpm), diastolic blood pres-
sure (50−90 mmHg), and systolic pressure (90−140
mmHg). Mean changes from baseline at Day 28 for ECG
parameters were small in all treatment groups and not
clinically meaningful overall.
Discussion
Results from this study for trough FEV1 indicate that
BID dosing regimens for glycopyrronium bromide pro-
duce slightly more bronchodilation compared with OD
regimens for an equivalent total daily dose. However,
over the course of the 24-hour dosing period, differences60 80 100




d intent-to-treat population). Model average values for OD and BID







































Total daily dose = 50 µg
0 6 12 18 24
Hours post-dose
Total daily dose = 100 µg
0 6 12 18
MCID
24
Figure 4 24-hour spirometry results at steady-state (modified intent-to-treat population). Model-based placebo-adjusted values for OD
and BID dosing regimens, with 90% confidence limits (red and blue shaded areas, respectively). MCID = 100 mL [12]. MCID: minimal clinically
important difference; FEV1: forced expiratory volume in one second; OD: once daily; BID: twice daily.
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dose, were negligible, and the dose–response relation-
ship for AUC0-24h FEV1 was driven primarily by total
daily dosage.
Dose–response results for FEV1 at 12 hours, FEV1
AUC0-12h and FEV1 AUC0-4h at steady-state showed that
OD regimens provided greater improvement over pla-
cebo than BID regimens for total daily doses of 25 μg,
50 μg and 100 μg, while the reverse was true for OD
versus BID regimens from 12–24 hours (see Table 2).
However, over the whole day these differences tend
to cancel out, thereby accounting for the lack of mean-
ingful differences between OD and BID dosing for AUC0-
24h. In theory, BID dosing may offer greater improvement
in night-time symptoms while OD regimens provide
greater improvements in day-time symptoms; the magni-
tude of the differences in spirometry data between the OD
and BID regimens suggests that any symptomatic differ-
ences would be also be small.
The 12.5 μg BID dose produced a marginally higher
improvement in trough FEV1 over placebo than the
50 μg OD dose at Day 28, however, the response it pro-
duced in FEV1 at 12 hours after 28 days of treatment
over placebo (74 mL) was below the MCID of 100 mL
[13]. These results therefore show that overall 50 μg
daily is the lowest daily dose of glycopyrronium bromide
to provide effective 24-hour bronchodilation. Of interest,
similar spirometric profiles were found to those shown
in the current study when aclidinium 400 μg BID wascompared with tiotropium 18 μg OD; improvements
from baseline in normalized FEV1 were significantly
greater for aclidinium vs tiotropium over the last
12 hours on days 1 and 15 [14].
It has been hypothesised that OD dosing may not offer
additional benefits over BID dosing in all patients; some
symptomatic patients may prefer more frequent relief
with a BID regimen [15]. However, simplification of dos-
ing regimens by reducing dosing frequency has been
shown to improve adherence with medication [16,17]
and has been linked with higher levels of persistence
[4,18,19]; increased adherence is strongly associated with
reduced hospitalization and healthcare utilization costs
[20,21]. It has also been suggested that bronchodilators
with long durations of action provide a relatively consist-
ent improvement in airway calibre over time, in contrast
to the peaks and troughs that can arise with bronchodi-
lators that are dosed twice-daily [22]. Assessment of the
dosing regimen(s) likely to provide optimum efficacy
should take into account whether adherence is likely to
be compromised by increased dosing frequency, and the
impact on potential non-adherence on the actual daily
dose received. It is also important to remember that ad-
herence tends to be lower in clinical practice than in a
clinical trial setting [23-28].
A 24-hour duration of action, combined with a rapid
onset of action, are desirable features in a novel LAMA.
Phase II and III studies have consistently shown that gly-
copyrronium bromide 50 μg OD is a suitable dosing
Table 3 Adverse events occurring during 28 days’ treatment with glycopyrronium bromide OD and BID treatment regimens
n (%) patients Glycopyrronium
bromide 12.5 μg
OD (n = 89)
Glycopyrronium
bromide 25 μg
OD (n = 96)
Glycopyrronium
bromide 12.5 μg
BID (n = 96)
Glycopyrronium
bromide 50 μg
OD (n = 92)
Glycopyrronium
bromide 25 μg
BID (n = 96)
Glycopyrronium
bromide 100 μg
OD (n = 96)
Glycopyrronium
bromide 50 μg
BID (n = 87)
Placebo
(n = 91)
Any AE 24 (27.0) 20 (20.8) 17 (17.7) 26 (28.3) 23 (24.0) 27 (28.1) 20 (23.0) 29 (31.9)
Any serious AE 2 (2.2) 2 (2.1) 1 (1.0) 3 (3.3) 4 (4.2) 3 (3.1) 1 (1.1) 3 (3.3)
Serious AE leading to discontinuation 2 (2.2) 1 (1.0) 1 (1.0) 1 (1.1) 2 (2.1) 2 (2.1) 0 2 (2.2)
Most common AEs by preferred term*
Nasopharyngitis 4 (4.5) 8 (8.3) 2 (2.1) 4 (4.3) 3 (3.1) 4 (4.2) 5 (5.7) 6 (6.6)
COPD worsening 7 (7.9) 3 (3.1) 2 (2.1) 0 5 (5.2) 3 (3.1) 1 (1.1) 4 (4.4)
Headache 1 (1.1) 1 (1.0) 2 (2.1) 3 (3.3) 3 (3.1) 4 (4.2) 3 (3.4) 6 (6.6)
Dyspnoea 0 2 (2.1) 3 (3.1) 3 (3.3) 2 (2.1) 1 (1.0) 4 (4.6) 0
Cough 3 (3.4) 3 (3.1) 1 (1.0) 0 1 (1.0) 3 (3.1) 0 2 (2.2)
Diarrhoea 1 (1.1) 2 (2.1) 3 (3.1) 0 1 (1.0) 0 2 (2.3) 0
Dry mouth 0 0 0 1 (1.1) 2 (2.1) 2 (2.1) 2 (2.3) 1 (1.1)
Lower RTI 0 0 1 (1.0) 0 3 (3.1) 1 (1.0) 0 0
*Occurring in ≥3 patients in any group.
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is sustained for 24-hours, and clinically meaningful effi-
cacy [5,6,8,9,29-31]. Recently published data show that
the pharmacokinetics of glycopyrronium bromide 50 μg
are consistent between doses with limited systemic accu-
mulation at steady-state after repeated once-daily inhal-
ation [32], indicating that glycopyrronium bromide
50 μg OD is also a suitable dosing regimen from a phar-
macokinetic perspective.
Spirometric measures are important endpoints and the
primary means of assessing bronchodilator efficacy in
clinical trials; however, symptomatic outcomes may be
more meaningful to patients and physicians. Such out-
comes should therefore be considered when assessing
the relative efficacy of different treatment regimens. It
cannot necessarily be assumed that a low-dose regimen
that provides equivalent efficacy in increasing FEV1 will
also provide equivalent efficacy on symptomatic end-
points. Indeed, a recent systematic review investigating
the relationship between FEV1 and other outcomes in
COPD found that improvements on the St. George’s
Respiratory Questionnaire (SGRQ) and Transition Dys-
pnoea Index correlated with FEV1 in part, but were
partly independent of changes in FEV1 [33]. Glycopyrro-
nium bromide 50 μg OD has been shown to effectively
improve COPD symptoms and reduce exacerbations: in
the Phase III GLOW1 study this treatment regimen pro-
duced a 108 mL difference in trough FEV1 (at 12 weeks)
compared with placebo (p < 0.001), which is comparable
to the difference reported in the present study (109 mL
versus placebo). In addition, it provided significant
improvements in dyspnoea, SGRQ and rescue medication
use versus placebo, accompanied by a 31% decreased risk
in moderate/severe exacerbations compared to placebo
(p = 0.023) [29].
Glycopyrronium bromide was well tolerated at all
doses investigated in this study. The incidence of AEs
was similar in glycopyrronium bromide - and placebo-
treated patients. The results support those from three
recently completed Phase III studies (GLOW1, GLOW2
and GLOW3) that show glycopyrronium bromide 50 μg
OD is well tolerated with a good overall safety profile
[6,29,30].
Overall, this study confirmed the efficacy of glycopyr-
ronium bromide 50 μg OD, as observed in other studies
[5,8], which identified this as an appropriate dosage for
further investigation in Phase III trials [6,29,30].
Conclusions
Differences in terms of FEV1 AUC0-24h between OD and
the same total daily dose administered BID were small
and not clinically relevant. Although both OD and BID
dosing appear to be viable, OD dosing is associated with
improved patient adherence; an important considerationwhen selecting the optimum dosing regimen for a novel
bronchodilator. Overall, the results of this study support
the efficacy and safety data from previous studies and re-
cently completed Phase III trials (GLOW1, GLOW2 and
GLOW3), which support glycopyrronium bromide 50 μg
OD as a safe, effective and convenient regimen that pro-
duces consistent, 24-hour bronchodilation.
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